向STAT3增强了CDK4/6抑制剂治疗在头部和部状细胞癌的作用
Lin Dong1, Chao Liu1, Haoyang Sun2
1Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Basic and Translational Medicine on Head & Neck Cancer, Tianjin, 300060, China; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin, 300060, China.
CDK4/6抑制剂在头部和部状细胞癌 (HNSCC) 中表现出有限的疗效. 通过对MYC进行上调,STAT3信号驱动电阻,导致RB缺乏. 将Stattic与CDK4/6抑制剂相结合,为HNSCC提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 头部和部状细胞癌 (HNSCC) 呈现CDK4/6过活化,但对抗CDK4/6治疗的反应往往有限.
- CDK4和CDK6的过度表达与HNSCC患者的预后不佳有关.
研究的目的:
- 研究HNSCC.中对CDK4/6抑制剂的耐药性机制.
- 确定新的治疗策略,以克服耐药性并改善治疗结果.
主要方法:
- 在HNSCC细胞系和患者样本中分析CDK4/6和STAT3信号通路.
- 在体外和体内研究评估了联合静态和CDK4/6抑制剂治疗的疗效.
- -STAT3水平,RB表达和患者预后之间的相关性分析.
主要成果:
- CDK4/6抑制激活了RB阳性HNSCC中的STAT3信号,导致MYC上调和RB缺乏.
- 结合Stattic和CDK4/6抑制剂治疗在体外和动物模型中显示出显著的抗瘤作用.
- 高-STAT3水平与减少RB表达相关,并预测HNSCC患者的预后不佳.
结论:
- 在HNSCC中,STAT3信号传递在赋予对CDK4/6抑制剂的耐药性方面发挥着关键作用.
- 针对CDK4/6和STAT3通路的组合疗法为HNSCC治疗提供了一个有前途的策略.
- -STAT3可以作为HNSCC治疗反应的预测生物标志物.
相关概念视频
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Drugs that Stabilize Microtubules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Positive Regulator Molecules


